FTC To Drop Antitrust Suit Over Lundbeck Heart Defect Drug
The Federal Trade Commission has decided not to ask the U.S. Supreme Court to revive its suit accusing Lundbeck Inc. of illegally cornering the market on drugs used to treat heart...To view the full article, register now.
Already a subscriber? Click here to view full article